Jubilant Ingrevia

Jubilant Ingrevia Limited has fully redeemed its Commercial Paper worth Rs. 50 crores on the maturity date of September 16, 2025. The Commercial Paper with ISIN INE0BY014391 was originally issued on July 18, 2025. The company completed the redemption as scheduled on the maturity date.

Jubilant Ingrevia Limited has fully redeemed its Commercial Paper worth Rs. 70 crores on September 15, 2025, which was the maturity date. The Commercial Paper with ISIN INE0BY014409 was originally issued on July 22, 2025. The company completed the redemption as scheduled on the maturity date.

Jubilant Ingrevia shares have gained 5% since mid-August after declining 14% following muted revenue growth in the June quarter. The chemical and nutrition products manufacturer derives 56% revenue from domestic operations with only 10% from US exports, limiting tariff impact. The European Union imposed 120% anti-dumping duty on Chinese choline chloride in July, benefiting the company which holds over 50% market share in India for this vitamin B4 product. The company allocated ₹600 crore capex for FY26, spending ₹54 crore in the June quarter to expand production capacity. Revenue breakdown shows specialty chemicals at 46%, chemical intermediaries at 37%, and nutrition products at 17%. Management reported volume uptick in agrochemicals, pharma, and consumer products after six to eight weak quarters. The company targets annualised savings exceeding ₹100 crore in FY26 through its Lean 2.0 cost optimization program. Existing plants at Bharuch and Gajraula will add 15-20% additional capacity, with a new multi-purpose plant construction beginning soon. Equirus Securities projects 34% annual growth in operating margin between FY25 and FY28.